Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sanofi's Lixisenatide Gets Clean Bill Of Health On CV Safety, Heart Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

ELIXA trial results show neither increased nor decreased risk of major adverse cardiovascular events; Sanofi's diabetes drug, still unapproved in the U.S., becomes the only GLP-1 receptor agonist with CV outcomes data.


Related Content

Sanofi's Lixisenatide Shows Challenges Of Being Late Entrant In Class
Sanofi's iGlarLixi: Two Formulations Raise FDA Red Flag On Dosing Errors
Empagliflozin CV Outcomes Data: Is Sum Of The Parts Greater Than Whole?
Will Novo’s LEADER Trial Move GLP-1 To The Front Line In High-Risk Diabetes?
Diabetes Manufacturers Brace Under Shifting Market Dynamics
Keeping Track: Sanofi Submits Lixisenatide NDA (Again); Sandoz Files Second Biosimilar Application
AstraZeneca: Combinations Are Key For GLP-1’s Next Evolutionary Step
Empagliflozin's CV Benefit Impresses At EASD, But What Will FDA Say?
FDA CV Requirements Sideline Sanofi’s Lixisenatide
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs


Related Companies